M
M.-C. Poon
Researcher at University of Calgary
Publications - 37
Citations - 2400
M.-C. Poon is an academic researcher from University of Calgary. The author has contributed to research in topics: Haemophilia & Medicine. The author has an hindex of 12, co-authored 20 publications receiving 2119 citations. Previous affiliations of M.-C. Poon include Foothills Medical Centre.
Papers
More filters
Journal ArticleDOI
Guidelines for the management of hemophilia.
A. Srivastava,A. K. Brewer,Evelien P. Mauser-Bunschoten,Nigel S. Key,Steve Kitchen,Adolfo Llinás,C. A. Ludlam,Johnny Mahlangu,K. Mulder,M.-C. Poon,Alison Street +10 more
TL;DR: These evidence‐based guidelines offer practical recommendations on the diagnosis and general management of hemophilia, as well as the management of complications including musculoskeletal issues, inhibitors, and transfusion‐transmitted infections.
Journal ArticleDOI
Home management of haemophilia
TL;DR: Home care was an essential prerequisite to the introduction of effective prophylactic factor replacement therapy, and the future holds the promise of factor concentrates for home use that have longer half‐lives, or can be administered by alternate routes.
Journal ArticleDOI
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience
Manuel Carcao,J. St Louis,M.-C. Poon,Eyal Grunebaum,S. Lacroix,A. M. Stain,Victor S. Blanchette,Georges-Etienne Rivard +7 more
TL;DR: It is suggested that rituximab may hold promise in the eradication of inhibitors in haemophiliacs where the likelihood of success of conventional ITI is poor.
Journal ArticleDOI
Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China
TL;DR: Low dose secondary prophylaxis significantly reduces frequency of joint bleeding; with moderate improvement in joint function, school attendance, sport participation and daily activities, although there are still unresolved issues.
Journal ArticleDOI
Short‐term low‐dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi‐centre pilot study in China
TL;DR: Short‐term low‐dose secondary prophylactic therapy is beneficial without increasing factors consumption for severe/moderate haemophilia patients with arthropathy in a multi‐centre setting in China.